Vaccine News, In Brief
Executive Summary
Varivax recommendation change: Varicella vaccination should be delayed from 12-18 months of age to 18-24 months due to a shortage of Merck's Varivax, the only approved varicella vaccine, the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices votes Feb. 20. Merck predicts supplies of Varivax will be sufficient to return to standard recommendations by early summer. Varivax supplies were affected by shutdown of company's West Point, Penn., manufacturing facility in late 2001 (1"The Pink Sheet" Feb. 11, p. 32)...
You may also be interested in...
Merck Vaccine Shipments Resume; CDC Varivax Orders On 8-Week Backlog
Merck has resumed shipments of all vaccine products following the shutdown of its West Point, Penn. manufacturing facility in late 2001
Influenza B Virus Strain For 2002-2003 Flu Season To Be Selected In March
The influenza B vaccine strain that will be used in the formulation for the 2002-2003 flu vaccine will be determined in March
FDA Drug Safety Committee Inaugural Meeting Tentatively Set For April
The FDA Drug Safety & Risk Management Subcommittee's first official meeting is tentatively set for April 22-23